Company research · Index
Medvi
GLP-1 telehealth built in 2 months for $20K. 16.2% net profit with a payroll of two brothers — the NYT audited the books. Runs on "telehealth-in-a-box" rails.
Editorial assessment · not an autonomy audit
The recorded proposition
Not an AI company — an old-fashioned middleman business turbocharged by AI.
Index summary of the positioning; not an independent finding.
Telehealth seller of GLP-1 weight-loss drugs, built in two months for $20,000 with a dozen-plus AI tools by Matthew Gallagher, working from home in LA. The category's verification outlier: the NYT audited its financials directly — $401M sales and 16.2% net profit in 2025 (Hims & Hers: 5.5% on 2,442 employees), tracking $1.8B for 2026. Bootstrapped, profitable, no valuation. The trick isn't just AI — it's 'telehealth-in-a-box' rails (CareValidate, OpenLoop Health) absorbing doctors, pharmacies, and compliance. Equally instructive as a cautionary tale: an FDA warning letter, an anti-spam class action over its affiliate marketers, and post-NYT reporting on fake AI doctor personas in its Meta ads. Sam Altman said the company won him a bet on when a near-one-person $1B business would appear.
Where humans remain involved
Ongoing human hours, approval frequency and intervention rates have not been measured in this record. Reported team size describes the company, not the labor required to operate a customer business.
What still needs evidence
Establish a repeatable production workflow, identify the tasks people still perform, and measure cost, reliability and customer outcomes before drawing conclusions about business autonomy.
Recorded caveat: FDA warning letter (Feb 2026); anti-spam class action (Mar 2026); AI-fake-doctor ads exposed
Financial and team context
Reported figures retain their original scope. Revenue periods and headcount dates may differ; these are not a current audited financial statement.
- Revenue
- $401M sales in 2025
2025-01-01 to 2025-12-31 · reported · Source not rechecked
Source: NYT (financials reviewed) ↗ - Reported team
- 2
Observation date unknown · team unspecified · Source not rechecked
Source: NYT (financials reviewed) ↗Disclosed contractors: 9 · Observation date unknown
- Funding as recorded
- $0 — bootstrapped and profitable
No field-specific source recorded.
Financial and headcount history · 4 observations
Recorded dates show when an entry was added to this history. Source-check dates show when the publication was read; they do not establish that the figure is current or audited. Earlier observations and corrections remain visible.
Disclosed contractors · 9
Observation date unknown · reported · unknown
Scope: medvi · contractors · Recorded 2026-09-12 · Source checked not recorded · Published date unknown
Imported from the existing research record; source not rechecked during import. Missing dates remain unknown.
NYT (financials reviewed) ↗Headcount · 2
Observation date unknown · unclassified · unknown
Scope: unknown · team unspecified · Recorded 2026-09-12 · Source checked not recorded · Published date unknown
Imported from the existing research record; source not rechecked during import. Missing dates remain unknown.
NYT (financials reviewed) ↗Revenue projection · $1.8B projected 2026 sales
2026-01-01 to 2026-12-31 · reported · approximate
Scope: medvi · Recorded 2026-09-12 · Source checked not recorded · Published date unknown
Separated from 2025 sales. Historical projection, not realized revenue; source not rechecked during import.
NYT (financials reviewed) ↗Revenue · $401M sales in 2025
2025-01-01 to 2025-12-31 · reported · approximate
Scope: medvi · Recorded 2026-09-12 · Source checked not recorded · Published date unknown
Imported from the existing research record; source not rechecked during import. Missing dates remain unknown.
NYT (financials reviewed) ↗
Valuation: None official (never raised)
Pricing and commercial terms
From $179 for the first month of GLP-1 medication.
Historical research snapshot. A pricing verification date is not recorded; confirm current plans, usage limits and additional costs with the provider before purchasing.
Recorded referral terms: Runs an affiliate-marketer network — the same channel at the center of the March 2026 anti-spam class action. These terms have not been revalidated for this profile.
Founders and recorded roles
Matthew Gallagher
41; self-taught coder (first project: a Weird Al fan page), no degree, ex-actor. Previous startup Watch Gang hit 60 employees and never turned a profit — the anti-headcount lesson behind Medvi. Advised by Kobie Fuller (Upfront Ventures) to skip VC entirely.
Elliot Gallagher
36; Matthew's brother and the only employee (hired April 2025) — filters all communications.
Recorded technology stack
- ChatGPT
- Claude
- Grok
- Midjourney
- Runway
- ElevenLabs
- Custom AI agents
- CareValidate
- OpenLoop Health
Components listed in the research record; integrations have not been independently tested here.
Research timeline
2026-04
NYT front page: 'A $1.8 Billion Business Built With A.I. and a Payroll of Just Two' — financials verified by the Times; Sam Altman says it won him a bet. Backlash follows: Techdirt and Futurism dispute the framing, and Business Insider finds thousands of Meta ads fronted by fake AI doctor personas.
Direct article link not recorded.
2026-03
Class action filed in the Central District of California alleging its affiliate marketers sent spam with spoofed domains and falsified headers ($1,000 sought per email).
Direct article link not recorded.
2026-02
FDA warning letter (Feb 20) for misbranding compounded semaglutide/tirzepatide — marketing implied FDA approval. Same month: men's health line launches and claims 50,000 customers in month one.
Direct article link not recorded.
2025-12
First full year closes at $401M sales, 250,000 customers, 16.2% net profit — with two employees, seven contract account managers, and two contract engineers.
Direct article link not recorded.
2024-09
Launches after a two-month, $20,000 build; 300 customers in month one, 1,000 more in month two.
Direct article link not recorded.
Sources and coverage limits
This profile brings together the existing Index research. Company announcements, sponsored articles and founder interviews can establish what was said; they do not independently prove sustained autonomy or revenue.